• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Primary thromboembolism prophylaxis may be effective in advanced cancer

byMonica ParksandDavid Wang
May 29, 2015
in Cardiology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a randomized controlled trial of over 300 patients with advanced pancreatic cancer treated in the outpatient setting, the use of a combined regimen of chemotherapy and prophylactic enoxaparin demonstrated significant reduction in the incidence of symptomatic venous thrombotic events compared to chemotherapy alone.

2. The addition of prophylactic enoxaparin did not result in an improvement in progression-free or overall survival compared to chemotherapy alone.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Due to their hypercoagulable state, patients with cancer are at greatly increased risk of venous thromboembolic events (VTEs). Advanced pancreatic cancer (APC) is associated with a one of the highest incidences of VTE, particularly if patients are undergoing systemic chemotherapy treatment. VTEs in this population result in impaired quality of life, delayed cancer treatment, increased hospitalizations, and increased medical expenses. While prophylactic anticoagulation is recommended for hospitalized patients, the role of VTE prophylaxis in the outpatient setting is unclear. The purpose of this randomized controlled trial was to evaluate the efficacy of anticoagulant use in the primary prevention of VTEs among outpatients with APC starting first-line chemotherapy.  The study randomized patients with APC to either the combination treatment (first-line chemotherapy and enoxaparin) or chemotherapy alone. At the conclusion of this trial, the patients in the combination therapy group demonstrated significantly lower incidence of symptomatic VTEs compared to the chemotherapy-alone group without increasing major bleeding events. The highest reduction in VTEs was observed within the first 3 months. Furthermore, there was no difference in progression-free or overall survival between the 2 groups. The results of this study support the use of outpatient prophylactic enoxaparin for the primary prevention of VTEs in patients with advanced pancreatic cancer. However, the study is limited by the open and non-blinded design, which may limit the validity of the study. Additional large, randomized trials are required to confirm the protective effect in patients with other primary cancers.

Click to read the study in JCO

Relevant Reading: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

In-Depth [prospective study]: This study was a prospective, open-label, randomized, multicenter trial of patients with APC starting treatment with outpatient chemotherapy. Eligibility criteria included outpatients with histologically-confirmed APC, no previous treatment with radiotherapy or chemotherapy, no VTEs within the past 2 years, and no pre-existing anticoagulation indications or contraindications. A total of 312 patients were enrolled and randomly assigned to chemotherapy with concomitant prophylactic enoxaparin or chemotherapy alone. Primary endpoints were the first event rate of symptomatic VTEs within 3 months after randomization, while secondary outcomes included median progression-free survival (PFS), median overall survival (OS), overall symptomatic VTEs within 3 months, and overall major bleeding rate. At the conclusion of the trial, there was a significant difference in the event rate of symptomatic VTEs at 3 months favoring combination therapy compared to chemotherapy alone  (HR: 0.12; 95% CI: 0.03-0.52; p = 0.001). There was no increase in the incidence of major bleeding events between the 2 groups (HR: 1.4; 95% CI: 0.35-3.72; p = 1.0). Overall, symptomatic VTEs occurred in 15.1% and 6.4% of the chemotherapy-only and combination groups, respectively (HR: 0.40; 95% CI: 0.19-0.83; p = 0.01). No significant differences were found between 2 two groups with respect to median PFS (p=0.64) or OS (p=0.44).

RELATED REPORTS

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

Preoperative biliary draining prior to pancreaticoduodenectomy not associated with increased complication risk

Artificial intelligence algorithm may increase atrial fibrillation detection rate in ambulatory setting

Image: CC/Wikimedia Commons/Yale Rosen

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anticoagulationpancreatic cancer
Previous Post

Financial incentive programs significantly improve smoking cessation

Next Post

Contrast-induced nephropathy may be less common than previously reported

RelatedReports

Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

November 29, 2022
Modified FOLFIRINOX results in longer disease-free survival in metastatic pancreatic cancer patients compared to gemcitabine
Gastroenterology

Preoperative biliary draining prior to pancreaticoduodenectomy not associated with increased complication risk

November 25, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Chronic Disease

Artificial intelligence algorithm may increase atrial fibrillation detection rate in ambulatory setting

October 19, 2022
VEGFR-targeted ultrasound may improve detection of pancreatic cancer
Oncology

Polycystic ovarian syndrome is associated with an increased risk of pancreatic cancer

October 17, 2022
Next Post
Contrast-induced nephropathy may be less common than previously reported

Contrast-induced nephropathy may be less common than previously reported

Kidney function metrics may help predict risk for cardiovascular disease

Kidney function metrics may help predict risk for cardiovascular disease

Danish case control study links oral contraceptives with glioma

Newer oral contraceptives linked with higher blood clot risk

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options